Navigation Links
Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line
Date:5/3/2010

VANCOUVER, May 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ( ANPI, TSX: ANP), a specialty pharmaceutical and medical device company, today announced that it has entered into an exclusive distribution agreement with B. Braun for its proprietary Quill(TM) SRS product line in the United Kingdom, Ireland, and France. The term of the distribution agreement will be for five years.

According to The Royal College of Surgeons of England, there are approximately 4.2 million surgical operations carried out every year in England alone. There are more than 18,000 surgeons currently practicing in England in approximately 2,900 operating theaters. According to market research, in France there are over 5 million surgical procedures performed annually by more than 17,000 surgeons in excess of 3,300 hospital facilities.

"We are very excited and proud to have one of the leading companies in wound closure partner with Angiotech to facilitate the continued acceptance of Quill(TM) SRS in these critical European countries," said Dr. William Hunter, President and CEO of Angiotech. "Having a leading company such as B. Braun, with its long legacy of innovation and technology leadership, join us as one of our European partners further validates Quill(TM) SRS's market potential as a transformational technology in the surgical market."

"We are very much looking forward to including the Quill(TM) SRS knotless suturing system in our comprehensive Closure Technologies portfolio and start redefining wound closure. Such innovat
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Inc. (NASDAQ: GNVC ) today announced the retirement ... of directors effective on October 24, 2014.   Dr. Horovitz joined ... chairman from June 2006 to November 2013.  During his tenure, ... Audit Committees of the board.  "We deeply ... to GenVec, and its stockholders," said Wayne T. Hockmeyer ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Millennium to Develop Additional Products for the ... Dec. 6 Millennium,Biotechnologies Inc., wholly owned ... Board: MBTG) today announced that the initial,$200,000.00 ... to,Provider Services, Inc. (PSI) under the previously ...
... Provides Support to Emerging Leader in Life Sciences R&D to ... ... 6 The New Jersey Economic,Development Authority (EDA) announced today ... the help of $4.9,million in tax-exempt bonds issued under the ...
... - Nventa,Biopharmaceuticals Corporation (TSX: NVN) today announced ... dosing of the second cohort of,patients in ... the safety of its,lead candidate, HspE7, in ... cancer. HspE7 is an investigational therapeutic vaccine ...
Cached Biology Technology:Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 3Edison Innovation Fund Helps Tris Pharma Expand 2Edison Innovation Fund Helps Tris Pharma Expand 3Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 2Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 3Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 4Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 5
(Date:10/18/2014)... Berlin, 19th October 2014 Psychological stress and stress-related ... for aging-related diseases, but the molecular mechanisms ... mechanisms may contribute to the development of ... treatments for these devastating diseases. This work ... Neuropsychopharmacology congress in Berlin., Now an international ...
(Date:10/17/2014)... have shown for the first time how bacteria can ... giving them the opportunity to get tremendous insights into ... study also discovered the bacterial growth in chronic lung ... slowed down by the immune cells. The researchers discovered ... "suffocate" the bacteria, forcing the bacteria to switch to ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... pluripotent stem cells were first derived in 2007, scientists have ... which are sourced in early-stage embryos. Both cell types ... body, but their origins in embryonic and adult tissue ... cell types have great potential in basic biological research and ...
... Boston Medical Center (BMC) have been awarded a four ... Institutes of Health (NIH) to study neurological and brain ... The study will be conducted under the direction of ... who also is the principal investigator of the study. ...
... The University of Utah is launching a six-year, $21.5 million ... for uses ranging from faster computers and communications devices to ... of Excellence in Materials Research and Innovation is being established ... from the National Science Foundation (NSF), $6.5 million for major ...
Cached Biology News:Study reveals critical similarity between two types of do-it-all stem cells 2Study reveals critical similarity between two types of do-it-all stem cells 3BMC awarded NIH grant to study brain abnormalities in former ELGANS patients 2$21.5 million for materials research at the University of Utah 2$21.5 million for materials research at the University of Utah 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... short-term enriched housing for nonhuman primates and ... non-quarantine settings on a per diem basis. ... state-of-the-art social housing and nursery facilities. In ... CDC quarantine facilities. Primate housing and ...
... some the things youll be telling others after ... by Erica Golemis, One look at the table ... topics in protein interaction will tell you immediately ... a part of your personal protein chemistry library. ...
Biology Products: